MCID: UTR043
MIFTS: 48

Uterine Sarcoma

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Uterine Sarcoma

MalaCards integrated aliases for Uterine Sarcoma:

Name: Uterine Sarcoma 49 51
Uterine Corpus Sarcoma 69
Sarcoma of the Uterus 49

Classifications:



Summaries for Uterine Sarcoma

MalaCards based summary : Uterine Sarcoma, also known as uterine corpus sarcoma, is related to leiomyoma and leiomyosarcoma. An important gene associated with Uterine Sarcoma is ABCB1 (ATP Binding Cassette Subfamily B Member 1), and among its related pathways/superpathways are Pathways in cancer and Gastric cancer. The drugs Doxorubicin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include uterus, smooth muscle and lung, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 72 The uterine sarcomas form a group of malignant tumors that arises from the smooth muscle or connective... more...

Related Diseases for Uterine Sarcoma

Diseases related to Uterine Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 117)
# Related Disease Score Top Affiliating Genes
1 leiomyoma 29.1 CYP19A1 DES ESR1 MME
2 leiomyosarcoma 28.8 DES KIT MB MDM2 PDGFRB WT1
3 adenosarcoma 28.0 DES ESR1 KIT MB MME
4 breast cancer 27.5 ABCB1 ABCC1 CDK2 CYP19A1 ESR1 KIT
5 endometrial stromal sarcoma 27.2 CYP19A1 DES ESR1 KIT MB MME
6 sarcoma 10.9
7 microsporidiosis 10.5 ABCB1 ABCC1
8 epithelioid cell melanoma 10.5 MCAM WT1
9 testicular gonadoblastoma 10.5 KIT WT1
10 colchicine resistance 10.5 ABCB1 ABCC1
11 kidney clear cell sarcoma 10.4 DES WT1
12 ovarian fibrothecoma 10.4 DES KIT
13 gallbladder sarcoma 10.3 DES KIT
14 retroperitoneal sarcoma 10.3 MDM2 SMARCB1
15 congenital mesoblastic nephroma 10.3 KIT SMARCB1 WT1
16 proliferative fasciitis 10.3 MB SMARCB1
17 core binding factor acute myeloid leukemia 10.3 KIT MVP WT1
18 spindle cell lipoma 10.3 DES MDM2
19 desmoid tumor 10.2 KIT PDGFRB
20 breast rhabdomyosarcoma 10.2 DES MB
21 giant cell myocarditis 10.2 DES MB
22 hypereosinophilic syndrome, idiopathic 10.2 KIT PDGFRB WT1
23 malignant triton tumor 10.2 DES MB
24 chronic eosinophilic leukemia 10.2 KIT PDGFRB WT1
25 sarcomatoid squamous cell skin carcinoma 10.2 KIT MB
26 cribriform carcinoma 10.2 ESR1 KIT
27 kidney rhabdoid cancer 10.2 MB SMARCB1 WT1
28 spindle cell rhabdomyosarcoma 10.2 DES MB
29 neurilemmoma 10.2 DES KIT SMARCB1
30 acute leukemia 10.2 ABCB1 KIT WT1
31 uterine inversion 10.2
32 adenoid basal cell carcinoma 10.2 ESR1 KIT
33 nervous system cancer 10.1 CDK2 MDM2 SMARCB1
34 conventional fibrosarcoma 10.1 KIT MDM2
35 lung leiomyoma 10.1 ESR1 MB
36 pulmonary vein stenosis 10.1 DES KIT
37 connective tissue cancer 10.1 KIT MDM2 SMARCB1
38 sclerosing liposarcoma 10.1 MB MDM2
39 bilateral retinoblastoma 10.1 DES MB
40 botryoid rhabdomyosarcoma 10.1 DES MB WT1
41 benign metastasizing leiomyoma 10.1 CYP19A1 DES
42 spindle cell synovial sarcoma 10.1 KIT MB SMARCB1
43 malignant peripheral nerve sheath tumor 10.1 KIT MDM2 SMARCB1
44 angiomyoma 10.1 CDK2 KIT MB
45 breast adenoid cystic carcinoma 10.1 ESR1 KIT
46 medullomyoblastoma 10.1 DES MB SMARCB1
47 embryonal sarcoma 10.1 DES KIT MDM2
48 myxosarcoma 10.1 ABCB1 MB MDM2
49 leukemia, chronic myeloid 10.0 ABCB1 KIT PDGFRB WT1
50 fibrosarcoma of bone 10.0 KIT MDM2 PDGFRB

Graphical network of the top 20 diseases related to Uterine Sarcoma:



Diseases related to Uterine Sarcoma

Symptoms & Phenotypes for Uterine Sarcoma

GenomeRNAi Phenotypes related to Uterine Sarcoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00107-A-1 9.91 DCK
2 Decreased viability GR00221-A-1 9.91 DCK ESR1 KIT PDGFRB SMARCB1
3 Decreased viability GR00221-A-2 9.91 DCK ESR1 SMARCB1
4 Decreased viability GR00221-A-3 9.91 PDGFRB SMARCB1
5 Decreased viability GR00221-A-4 9.91 DCK ESR1 PDGFRB
6 Decreased viability GR00240-S-1 9.91 DCK
7 Decreased viability GR00301-A 9.91 KIT
8 Decreased viability GR00342-S-1 9.91 PDGFRB
9 Decreased viability GR00381-A-1 9.91 SMARCB1
10 Increased HPV16-GFP infection GR00350-A 8.92 ABCC1 DCK DES PGRMC1

MGI Mouse Phenotypes related to Uterine Sarcoma:

43 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.31 PDGFRB SMARCB1 WT1 MCAM MDM2 KIT
2 homeostasis/metabolism MP:0005376 10.28 WT1 PDGFRB SMARCB1 MCAM MDM2 KIT
3 hematopoietic system MP:0005397 10.27 SMARCB1 WT1 MCAM MDM2 KIT MB
4 cellular MP:0005384 10.26 WT1 PDGFRB SMARCB1 MB MDM2 KIT
5 behavior/neurological MP:0005386 10.25 PDGFRB PGRMC1 SMARCB1 ESR1 MCAM MDM2
6 immune system MP:0005387 10.22 WT1 PDGFRB SMARCB1 MCAM MDM2 KIT
7 endocrine/exocrine gland MP:0005379 10.13 WT1 PDGFRB ESR1 MDM2 KIT CDK2
8 embryo MP:0005380 10.1 WT1 PDGFRB SMARCB1 MB ESR1 MDM2
9 mortality/aging MP:0010768 10.06 WT1 PDGFRB SMARCB1 MB ESR1 MDM2
10 digestive/alimentary MP:0005381 10.05 PDGFRB SMARCB1 ESR1 MDM2 KIT CYP19A1
11 liver/biliary system MP:0005370 10.02 WT1 SMARCB1 MDM2 KIT MME CDK2
12 muscle MP:0005369 9.96 SMARCB1 WT1 PDGFRB MDM2 KIT MB
13 neoplasm MP:0002006 9.63 WT1 SMARCB1 ESR1 MDM2 KIT CDK2
14 normal MP:0002873 9.56 WT1 PDGFRB ESR1 MDM2 KIT MVP
15 reproductive system MP:0005389 9.28 WT1 PDGFRB SMARCB1 ESR1 MDM2 KIT

Drugs & Therapeutics for Uterine Sarcoma

Drugs for Uterine Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 177)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
3
Cisplatin Approved Phase 3,Phase 2 15663-27-1 2767 441203 84093
4
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
5
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
6
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
7
Morphine Approved, Investigational Phase 3 57-27-2 5288826
8
Methylphenidate Approved, Investigational Phase 3 20748-11-2, 113-45-1 4158
9
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
10
Mesna Approved, Investigational Phase 3 3375-50-6 598
11
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
13
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
14
Cyproheptadine Approved Phase 3 129-03-3 2913
15
Bevacizumab Approved, Investigational Phase 3 216974-75-3
16
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
17
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
18
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
19 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
20 Isophosphamide mustard Phase 3,Phase 2,Phase 1 0
21 Alkylating Agents Phase 3,Phase 2,Phase 1
22 Albumin-Bound Paclitaxel Phase 3,Phase 2
23 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
24 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
25 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
26 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
27 Anti-Infective Agents Phase 3,Phase 2,Phase 1
28 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
29 Antimetabolites Phase 3,Phase 2,Phase 1
30 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
31 Antimitotic Agents Phase 3,Phase 2,Phase 1
32 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
33 Liver Extracts Phase 3,Phase 1,Phase 2
34 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
35 Antiviral Agents Phase 3,Phase 2,Phase 1
36 Analgesics Phase 3,Phase 2,Phase 1
37 Central Nervous System Depressants Phase 3
38 Adjuvants, Anesthesia Phase 3
39 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
40 Mitogens Phase 3,Phase 2
41 Narcotics Phase 3
42 Analgesics, Opioid Phase 3
43 Anesthetics Phase 3
44 Anesthetics, General Phase 3
45 Anesthetics, Intravenous Phase 3
46 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
47 Endothelial Growth Factors Phase 3,Phase 2
48 Epoetin alfa Phase 3 113427-24-0
49 Gastrointestinal Agents Phase 3,Phase 2
50 Antibodies, Monoclonal Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 118)

# Name Status NCT ID Phase Drugs
1 The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3 doxorubicin, ifosfamide, cisplatin
2 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
3 Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus Completed NCT00002706 Phase 3
4 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
5 Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus Completed NCT00003128 Phase 3 ifosfamide;paclitaxel
6 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus Completed NCT00002546 Phase 3 cisplatin;ifosfamide
7 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
8 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
9 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
10 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
11 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
12 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
13 Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Active, not recruiting NCT01533207 Phase 3 Docetaxel;Doxorubicin Hydrochloride;Gemcitabine Hydrochloride
14 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
15 Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms Active, not recruiting NCT01376349 Phase 3 prasterone
16 Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Terminated NCT01012297 Phase 3 Docetaxel;Gemcitabine Hydrochloride
17 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
18 Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers Unknown status NCT02052128 Phase 1, Phase 2 onapristone
19 Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma Unknown status NCT00033709 Phase 2 temozolomide;thalidomide
20 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
21 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
22 Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer Unknown status NCT00905658 Phase 2
23 Chemotherapy in Treating Patients With Sarcoma of the Uterus Completed NCT00005643 Phase 2 pegylated liposomal doxorubicin hydrochloride
24 Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00378911 Phase 2 sunitinib malate
25 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00075400 Phase 2 imatinib mesylate
26 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
27 Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01637961 Phase 2 Alisertib
28 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Completed NCT00238121 Phase 2 sorafenib tosylate
29 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
30 Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy Completed NCT01220609 Phase 2 Ixabepilone
31 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
32 Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00031629 Phase 2 Docetaxel;Gemcitabine Hydrochloride
33 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
34 Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00025220 Phase 2 Thalidomide
35 Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer Completed NCT00112489 Phase 2 carboplatin;paclitaxel
36 Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma Completed NCT00101127 Phase 2 docetaxel;gemcitabine hydrochloride
37 Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus Completed NCT00379145 Phase 2 trabectedin
38 Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00003778 Phase 2 dolastatin 10
39 Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery Completed NCT01553539 Phase 2 therapeutic angiotensin-(1-7)
40 Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies Completed NCT01079832 Phase 2
41 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
42 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2 ziv-aflibercept
43 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
44 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
45 Thalidomide in Treating Patients With Gynecologic Sarcomas Completed NCT00006005 Phase 2 thalidomide
46 Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer Completed NCT00032162 Phase 1, Phase 2 carboplatin;pegylated liposomal doxorubicin hydrochloride
47 Chemotherapy in Treating Patients With Advanced Sarcoma Completed NCT00002526 Phase 2 doxorubicin hydrochloride;ifosfamide
48 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
49 Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma Completed NCT00227669 Phase 2 docetaxel;gemcitabine hydrochloride
50 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide

Search NIH Clinical Center for Uterine Sarcoma

Genetic Tests for Uterine Sarcoma

Anatomical Context for Uterine Sarcoma

MalaCards organs/tissues related to Uterine Sarcoma:

38
Uterus, Smooth Muscle, Lung, Brain, Bone, Endothelial, T Cells

Publications for Uterine Sarcoma

Articles related to Uterine Sarcoma:

(show top 50) (show all 304)
# Title Authors Year
1
Treatment of Uterine Sarcoma with rAd-p53 (Gendicine) Followed by Chemotherapy: Clinical Study of TP53 Gene Therapy. ( 29281902 )
2018
2
Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study. ( 29185261 )
2018
3
Utility of Clinical Parameters and Multiparametric MRI as Predictive Factors for Differentiating Uterine Sarcoma From Atypical Leiomyoma. ( 29422425 )
2018
4
Clinical Characteristics Differentiating Uterine Sarcoma and Fibroids. ( 29398899 )
2018
5
Reducing the spread of occult uterine sarcoma at the time of minimally invasive gynecologic surgery. ( 29128980 )
2018
6
RNA-sequencing identifies novel GREB1-NCOA2 fusion gene in a uterine sarcoma with the chromosomal translocation t(2;8)(p25;q13). ( 29218853 )
2018
7
Magnetic resonance imaging features of uterine sarcoma and mimickers. ( 28246921 )
2017
8
Undifferentiated Uterine Sarcoma: An Uncommon Case Report. ( 28511398 )
2017
9
18F-FDG/18F-FES standardized uptake value ratio determined using PET predicts prognosis in uterine sarcoma. ( 28186981 )
2017
10
Optimizing Local Control in High-Grade Uterine Sarcoma: Adjuvant Vaginal Vault Brachytherapy as Part of a Multimodal Treatment. ( 28174295 )
2017
11
Uterine epithelioid leiomyosarcoma with c-kit expression and YWHAE gene rearrangement: a case report of a diagnostic pitfall of uterine sarcoma. ( 28288693 )
2017
12
Role of Lymphadenectomy for Uterine Sarcoma: A Meta-Analysis. ( 27668397 )
2017
13
Multi-institutional study of peritoneal sarcomatosis from uterine sarcoma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. ( 28967566 )
2017
14
Frequency of uterine sarcomas in patients admitted for uterine fibroid surgery. ( 28400352 )
2017
15
Unsuspected Uterine Sarcoma in an Urban Hospital: Does Surgical Approach Matter? ( 29061369 )
2017
16
Cytotoxic effects of 15-deoxy-I912,14-prostaglandin J2 alone and in combination with dasatinib against uterine sarcoma in vitro. ( 28587364 )
2017
17
Safety of ovarian preservation in premenopausal women with stage I uterine sarcoma. ( 28541635 )
2017
18
Elevated levels of serum MiR-152 and miR-24 in uterine sarcoma: potential for inducing autophagy via SIRT1 and deacetylated LC3. ( 28929922 )
2017
19
Uterine sarcoma - current perspectives. ( 28919822 )
2017
20
Efficacy of PET/CT to exclude leiomyoma in patients with lesions suspicious for uterine sarcoma on MRI. ( 28805609 )
2017
21
Does the patients age at cancer diagnosis affect microvessels density in uterine sarcoma tissues? ( 28397202 )
2017
22
Uterine sarcoma with ambiguous histomorphology: A case report. ( 28271093 )
2017
23
Pulmonary Metastasis of Undifferentiated Uterine Sarcoma Forming Fluid-Containing Cyst. ( 28862061 )
2017
24
Establishment and characterization of uterine sarcoma and carcinosarcoma patient-derived xenograft models. ( 28625393 )
2017
25
A Multicentre Retrospective Review of Clinical Characteristics of Uterine Sarcoma. ( 28729098 )
2017
26
Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma. ( 28643014 )
2017
27
Morcellation of undiagnosed uterine sarcoma: A critical review. ( 26672915 )
2016
28
Laparoscopic surgery on broken points for uterine sarcoma in the early stage decrease prognosis. ( 27503773 )
2016
29
Clinical Characteristics and Prognosis of Unexpected Uterine Sarcoma After Hysterectomy for Presumed Myoma With and Without Transvaginal Scalpel Morcellation. ( 26807642 )
2016
30
Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072. ( 27012429 )
2016
31
A Retrospective Analysis of the Impact of Myomectomy on Survival in Uterine Sarcoma. ( 26828206 )
2016
32
Outcomes of uterine sarcoma found incidentally after uterus-preserving surgery for presumed benign disease. ( 27553655 )
2016
33
Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy for Benign Indications. ( 26855091 )
2016
34
Occult Uterine Sarcoma and Leiomyosarcoma: Incidence of and Survival Associated With Morcellation. ( 26646120 )
2016
35
Uterine sarcoma Part II-Uterine endometrial stromal sarcoma: The TAG systematic review. ( 27590366 )
2016
36
Uterine Sarcoma: Analysis of 13,089 Cases Based on Surveillance, Epidemiology, and End Results Database. ( 27177280 )
2016
37
Correction: A Retrospective Analysis of the Impact of Myomectomy on Survival in Uterine Sarcoma. ( 27078148 )
2016
38
Risk of Occult Uterine Sarcoma in Presumed Uterine Fibroids. ( 26645385 )
2016
39
Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy. ( 27208537 )
2016
40
Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy for Benign Indications: Correction. ( 28605356 )
2016
41
Differential diagnosis between uterine sarcoma and leiomyoma using preoperative clinical characteristics. ( 26695124 )
2016
42
Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand. ( 27221849 )
2016
43
Uterine sarcoma vs adenocarcinoma: can MRI distinguish between them? ( 26617259 )
2016
44
Uterine sarcoma part III-Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review. ( 27751406 )
2016
45
Uterine sarcoma Part I-Uterine leiomyosarcoma: The Topic Advisory Group systematic review. ( 27590365 )
2016
46
A uterus soaked in blood with low haemoglobin in a case of unrecognized uterine sarcoma. ( 27048123 )
2016
47
Curative effect of bevacizumab combined with chemotherapy in advanced or recurrent uterine sarcoma. ( 26893869 )
2016
48
A Multi-Center Retrospective Review of Clinical Characteristics of Uterine Sarcoma. ( 27679381 )
2015
49
A Comparative Study of the Methods of Diagnosis and Outcomes of Different Uterine Sarcoma Types. ( 27679119 )
2015
50
Genistein Suppresses Growth of Human Uterine Sarcoma Cell Lines via Multiple Mechanisms. ( 26026076 )
2015

Variations for Uterine Sarcoma

Expression for Uterine Sarcoma

Search GEO for disease gene expression data for Uterine Sarcoma.

Pathways for Uterine Sarcoma

Pathways related to Uterine Sarcoma according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1 12.58 CDK2 ESR1 KIT MDM2 PDGFRB
2
Show member pathways
12.47 ABCB1 CDK2 ESR1 KIT SMARCB1
3 12.3 ABCB1 ABCC1 MDM2 PDGFRB
4 11.84 ABCB1 ABCC1 CYP19A1 MB PGRMC1
5 11.77 CDK2 MDM2 PDGFRB
6 11.75 CDK2 CYP19A1 ESR1 MDM2
7 11.67 DES KIT MCAM
8 11.6 CDK2 DCK MDM2
9
Show member pathways
11.34 ABCB1 KIT PDGFRB
10 11.25 CDK2 MDM2 SMARCB1
11
Show member pathways
10.86 ABCB1 ABCC1
12 10.71 ABCB1 ABCC1
13 10.61 ABCB1 ABCC1
14 10.43 ABCB1 ABCC1
15 10.05 ABCB1 ABCC1 DCK
16 9.76 CYP19A1 ESR1

GO Terms for Uterine Sarcoma

Biological processes related to Uterine Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of DNA binding transcription factor activity GO:0051091 9.63 ESR1 KIT SMARCB1
2 cell chemotaxis GO:0060326 9.5 ABCC1 KIT PDGFRB
3 androgen metabolic process GO:0008209 9.48 CYP19A1 ESR1
4 uterus development GO:0060065 9.43 CYP19A1 ESR1
5 cellular response to estrogen stimulus GO:0071391 9.4 ESR1 MDM2
6 xenobiotic transport GO:0042908 9.37 ABCB1 ABCC1
7 metanephric mesenchyme development GO:0072075 9.26 PDGFRB WT1
8 male gonad development GO:0008584 9.26 ESR1 KIT PDGFRB WT1
9 metanephric S-shaped body morphogenesis GO:0072284 9.16 PDGFRB WT1
10 positive regulation of phospholipase C activity GO:0010863 8.8 ESR1 KIT PDGFRB

Molecular functions related to Uterine Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 xenobiotic transmembrane transporting ATPase activity GO:0008559 8.62 ABCB1 ABCC1

Sources for Uterine Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....